

Pan Pan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11371268/publications.pdf>

Version: 2024-02-01

11
papers

352
citations

1163117

8
h-index

1372567

10
g-index

13
all docs

13
docs citations

13
times ranked

574
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting InhA, the FASII Enoyl-ACP Reductase: SAR Studies on Novel Inhibitor Scaffolds. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 672-693.	2.1	76
2	A Structural and Energetic Model for the Slow-Onset Inhibition of the <i>Mycobacterium tuberculosis</i> Enoyl-ACP Reductase InhA. <i>ACS Chemical Biology</i> , 2014, 9, 986-993.	3.4	63
3	Rational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase Inhibitor. <i>Journal of Biological Chemistry</i> , 2014, 289, 15987-16005.	3.4	63
4	Rational Optimization of Drug-Target Residence Time: Insights from Inhibitor Binding to the <i>Staphylococcus aureus</i> FabI Enzyme-Product Complex. <i>Biochemistry</i> , 2013, 52, 4217-4228.	2.5	58
5	Time-Dependent Diaryl Ether Inhibitors of InhA: Structure-Activity Relationship Studies of Enzyme Inhibition, Antibacterial Activity, and <i>in vivo</i> Efficacy. <i>ChemMedChem</i> , 2014, 9, 776-791.	3.2	48
6	Regioselective modification of amino groups in aminoglycosides based on cyclic carbamate formation. <i>Tetrahedron</i> , 2008, 64, 9078-9087.	1.9	15
7	Selective deprotection of the Cbz amine protecting group for the facile synthesis of kanamycin A dimers linked at N-3 position. <i>Tetrahedron</i> , 2009, 65, 5922-5927.	1.9	10
8	Radiolabelling and positron emission tomography of PT70, a time-dependent inhibitor of InhA, the <i>Mycobacterium tuberculosis</i> enoyl-ACP reductase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4782-4786.	2.2	9
9	Selectivity of Pyridone- and Diphenyl Ether-Based Inhibitors for the <i>Yersinia pestis</i> FabV Enoyl-ACP Reductase. <i>Biochemistry</i> , 2016, 55, 2992-3006.	2.5	6
10	Formulation studies of InhA inhibitors and combination therapy to improve efficacy against <i>Mycobacterium tuberculosis</i> . <i>Tuberculosis</i> , 2016, 101, 8-14.	1.9	4
11	Residence Time and <i>in vivo</i> Antibacterial Activity - A Critical Aspect of Lead Compound Optimization. <i>FASEB Journal</i> , 2010, 24, 680.3.	0.5	0